Previous Article | Next Article ![]()
Infect Immun, February 1998, p. 540-548, Vol. 66, No. 2
Departments of
Microbiology,1
Pediatrics,2 and
Biochemistry,3 University of Texas
Southwestern Medical Center, Dallas, Texas 75235-9048
Received 1 July 1997/Returned for modification 13 August
1997/Accepted 21 November 1997
A monoclonal antibody (MAb) (MAb 10F3) directed against the CopB
outer membrane protein of Moraxella catarrhalis previously was found to enhance pulmonary clearance of M. catarrhalis
in an animal model (M. Helminen, I. Maciver, J. L. Latimer,
L. D. Cope, G. H. McCracken, Jr., and E. J. Hansen,
Infect. Immun. 61:2003-2010, 1993). In the present study, this same
MAb was shown to exert complement-dependent bactericidal activity
against this pathogen in vitro. Nucleotide sequence analysis of the
copB gene from two MAb 10F3-reactive and two MAb
10F3-unreactive strains of M. catarrhalis revealed that the
deduced amino acid sequences of these four CopB proteins were at least
90% identical. Comparison of the amino acid sequences of these
proteins allowed localization of possible MAb 10F3 binding sites to
five relatively small regions of the CopB protein from M. catarrhalis O35E. When five synthetic peptides representing these
regions were tested for their ability to bind MAb 10F3 in a direct
enzyme-linked immunosorbent assay system, an oligopeptide containing 26 amino acids was shown to bind this MAb. The actual binding region for
MAb 10F3 was localized further through the use of overlapping
decapeptides that spanned this 26-mer. A fusion protein containing the
same 26-mer readily bound MAb 10F3 and was used to immunize mice. The
resultant antiserum contained antibodies that reacted with the CopB
protein of the homologous M. catarrhalis strain in Western
blot analysis and bound to the surface of both homologous and
heterologous strains of M. catarrhalis.
Moraxella
(Branhamella) catarrhalis is an important
respiratory tract pathogen. In children, this organism is the third
most common etiologic agent of acute bacterial otitis media and
accounts for up to 20% of cases (3, 11, 18). In a recent
report, M. catarrhalis DNA could be detected by performing
PCR on middle ear fluid from 46% of patients with chronic otitis media
with effusion (41). In adults, M. catarrhalis is
a frequent cause of acute exacerbations of chronic obstructive
pulmonary disease (10, 24, 34, 38). Invasive infections with
this organism, such as bacteremia, meningitis, skeletal infections, and
endocarditis, are rare and occur mainly in immunocompromised
individuals (12, 33).
The wide occurrence of M. catarrhalis infections and the
rapid spread of The lack of a polysaccharide capsule surrounding M. catarrhalis indicates that surface-exposed outer membrane antigens
are the likely targets for a protective immune response. Different M. catarrhalis strains have remarkably similar outer
membrane protein profiles (4, 35), and at least three
surface-exposed proteins of this organism appear to be well conserved
antigenically (26, 27, 29, 36). One of these, the 80-kDa
CopB protein (also designated OMP B2), is a potential vaccine
candidate, based on the finding that a monoclonal antibody (MAb) (MAb
10F3) directed against a surface-exposed CopB epitope reacted with
approximately 70% of M. catarrhalis strains and enhanced
pulmonary clearance of M. catarrhalis in a murine model
(26). It has been established that CopB expression is iron
regulated (2, 5) and that CopB is involved at some level in
the ability of M. catarrhalis to acquire iron from human
transferrin and lactoferrin (2). Expression of CopB is
apparently essential for virulence of M. catarrhalis, at
least in an animal model, because an isogenic copB mutant
was less able than its wild-type parent strain to resist clearance from
the lungs of mice (28).
In this study, MAb 10F3 was shown to be bactericidal against MAb
10F3-reactive strains. Comparison of the deduced amino acid sequences
of the CopB proteins from four strains of M. catarrhalis revealed a high degree of identity among these proteins, which in turn
facilitated mapping of the MAb 10F3-reactive epitope. These data
allowed construction of a fusion protein which bound MAb 10F3 and
induced the synthesis of antibodies directed against the surface of
M. catarrhalis.
(Part of this research was presented by C. Aebi et al. at the 36th
Interscience Conference on Antimicrobial Agents and Chemotherapy, New
Orleans, La., 18 September 1996 [1a].)
Bacterial strains, plasmids, and growth conditions.
The
bacterial strains and plasmids used in this study are listed in Table
1. M. catarrhalis O35E has
been described in detail previously (26, 28). M. catarrhalis strains were routinely cultured at 37°C on brain
heart infusion (BHI) agar plates (Difco Laboratories, Detroit, Mich.)
in an atmosphere of 95% air-5% CO2 or in BHI broth. The
Escherichia coli cloning strains RR1, HB101, and DH5
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Mapping of a Protective Epitope of the CopB Outer
Membrane Protein of Moraxella catarrhalis
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
-lactamase production among clinical isolates have stimulated efforts to develop a vaccine against this pathogen (1). Several lines of evidence suggest that the induction of appropriate humoral immunity will likely be protective against respiratory tract disease caused by M. catarrhalis. (i)
Acute M. catarrhalis infection induces the production of
both serum and secretory antibodies against various antigenic
determinants of this pathogen (17, 25, 44). (ii) The
age-dependent development of the humoral response against M. catarrhalis is inversely related to the prevalence of
nasopharyngeal colonization and incidence of otitis media involving
M. catarrhalis (20, 45). (iii) Passive immunization with M. catarrhalis-directed antibodies as well
as active immunization with M. catarrhalis outer membrane
proteins enhanced pulmonary clearance of M. catarrhalis in
an animal model (26, 27, 32).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
and
recombinant strains were grown on Luria-Bertani medium (42)
supplemented, when necessary, with an appropriate antimicrobial compound.
TABLE 1.
Bacterial strains and plasmids used in this study
Outer membrane protein preparations and Western blot analysis. Outer membrane vesicles were prepared from BHI broth-grown M. catarrhalis strains as described previously (37). Proteins present in these outer membrane vesicles were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detected by Western blot analysis as described previously (26).
MAbs and polyclonal antisera. MAb 10F3 is a murine IgG2a antibody reactive with a surface-exposed epitope of the CopB outer membrane protein of M. catarrhalis O35E and O12E (26). This MAb does not bind to the CopB protein expressed by M. catarrhalis TTA24 and O46E (26). This MAb was used in the form of hybridoma culture supernatant fluid for enzyme-linked immunosorbent assays (ELISAs), epitope mapping, and Western blot analysis and in the indirect antibody accessibility assay. For use in bactericidal assays, MAb 10F3 was purified by using protein A-Sepharose CL-4B (Pharmacia Biotech Inc., Piscataway, N.J.) as described previously (15). MAb 17C7 is a murine immunoglobulin G (IgG) antibody directed against the UspA surface antigen of M. catarrhalis (27). MAb 3F12 is a murine IgG antibody specific for the major outer membrane protein (MOMP) of Haemophilus ducreyi (21). The last two of these MAbs were used as negative controls in the ELISA and indirect antibody accessibility assays, respectively. Polyclonal rabbit antiserum raised against M. catarrhalis TTA24 outer membrane vesicles was described previously (26).
Cloning and nucleotide sequence analysis of the copB gene of M. catarrhalis strain TTA24. Chromosomal DNA obtained from this strain was partially digested with PstI (Gibco BRL, Gaithersburg, Md.) and then subjected to agarose gel electrophoresis. Fragments (6 to 9 kb) were purified by using the GeneCleanII kit (BIO 101 Inc., La Jolla, Calif.); these fragments were ligated overnight at 16°C into PstI-digested and alkaline phosphatase-treated pBR322 (New England Biolabs Inc., Beverly, Mass.) by using T4 DNA ligase (Gibco BRL). The ligation reaction mixture was used to transform competent E. coli RR1 cells. Colony material from tetracycline-resistant transformants was transferred to nitrocellulose pads and treated with UV light (UV Stratalinker; Stratagene, La Jolla, Calif.) to bind DNA to the nitrocellulose. These membranes were probed with a 32P-labeled 1.3-kb PvuII-XbaI fragment from the copB gene of M. catarrhalis O35E (26). Clones that hybridized this copB gene probe were tested for expression of the CopB protein by Western blot analysis.
PCR-based amplification and nucleotide sequence analysis of the copB genes of M. catarrhalis strains O12E and O46E. Chromosomal DNA from M. catarrhalis strains O12E and O46E was extracted by standard methods and used as the template DNA in a PCR system together with primers derived from the nucleotide sequence of the copB gene from M. catarrhalis O35E (26). With a PTC 100 Programmable Thermal Controller (MJ Research, Inc., Cambridge, Mass.) and the GeneAmp PCR kit (Roche Molecular Systems Inc., Branchburg, N.J.), a 2.5-kb DNA fragment containing the copB gene was amplified from each strain. With Spin-X centrifuge tube filters (Corning Costar Corp., Cambridge, Mass.), these 2.5-kb PCR products were extracted from 0.7% agarose gel slices and resuspended in water. The nucleotide sequences of these two PCR products were determined with a model 373 DNA sequencer (Applied Biosystems, Inc., Foster City, Calif.), used according to the manufacturer's protocol. The sequencing reactions were performed with the Applied Biosystems PRISM Ready Reaction DiDeoxy Terminator Cycle Sequencing Kit with AmpliTaq DNA Polymerase, according to the manufacturer's directions (Applied Biosystems, Inc.). Sequencing primers were designed from the nucleotide sequence of the copB gene from M. catarrhalis O35E (26) or from the individual copB sequences.
Oligopeptide synthesis. Oligopeptides were synthesized on a Symphony Peptide Synthesizer (Rainin Instrument Co., Inc., Woburn, Mass.) by the Biopolymers Facility, Howard Hughes Medical Institute, Dallas, Tex. The molecular weight and purity of the peptides were determined by high-performance liquid chromatography and mass spectrometry.
ELISA. Flat-bottom microtiter ELISA plates (Corning Glass Ware, Corning, N.Y.) were coated with outer membrane vesicles (5 µg) from M. catarrhalis O35E or with synthetic peptides (10 µg) in 50 mM sodium carbonate buffer (pH 9.6) with or without 2% (vol/vol) fresh glutaraldehyde and incubated overnight at 4°C. After washing three times with phosphate-buffered saline (PBS)-Tween (PBS containing 0.05% [vol/vol] Tween 20 and 0.025% [wt/vol] sodium azide) and blocking with PBS-Tween containing 1% (wt/vol) bovine serum albumin for 1 h, 100-µl portions of MAb 10F3 or MAb 17C7 (negative control) or mouse antiserum in dilutions of 1:10 to 1:1,000 in blocking buffer were added and the plates were incubated at 37°C for 1 h. After washing, antibody binding to peptides was detected by using alkaline phosphatase-conjugated goat anti-mouse IgG (Organon Teknika Corp., West Chester, Pa.) with p-nitrophenylphosphate (Sigma Chemicals Co., St. Louis, Mo.) in 10% (vol/vol) diethanolamine buffer (pH 9.8) as the enzyme substrate. Absorbance at 410 nm was measured with an MR 700 Microplate reader (Dynatech Laboratories, Chantilly, Va.).
Fine mapping of the MAb 10F3-reactive epitope. Overlapping synthetic decapeptides that were N-terminally bound to a membrane composed of derivatized cellulose were obtained from Research Genetics Inc., Huntsville, Ala. After five washes with PBS-Tween, the membrane was blocked for 1 h at room temperature in PBS-Tween containing 10% (wt/vol) nonfat dry milk and subsequently incubated with MAb 10F3 overnight at 4°C. Following three washes with PBS-Tween, the membrane was incubated overnight at 4°C with gentle rocking with 106 cpm of radioiodinated (specific activity, 2 × 107 cpm/µg protein), affinity-purified goat anti-mouse immunoglobulin. The membrane was then washed as described above and exposed to X-ray film (Fuji RX safety film; Fuji Industries, Tokyo, Japan).
Construction of a GST fusion protein expressing the MAb
10F3-reactive epitope.
The pGEX-4T-2 expression vector system
(Pharmacia Biotech Inc.) was used to construct a fusion protein
containing the MAb 10F3-reactive epitope at the C terminus of
glutathione-S-transferase (GST). By using the
oligonucleotide primers 5'-CGGGATCCCTAGATATAGAAAAAGAT-3' and
5'-CCGCTCGAGCTTGCCTCGATATTTGTTATC-3' derived from the
copB gene sequence of M. catarrhalis O35E and
containing a BamHI or an XhoI restriction site at
their 5' ends, respectively, a 78-bp fragment encoding amino acid
residues 275 to 300 of the CopB protein (i.e., peptide R1 [see Fig.
2]) was amplified from M. catarrhalis O35E chromosomal DNA
by PCR, digested with BamHI and XhoI, and ligated
into BamHI- and XhoI-digested pGEX-4T-2 by using
T4 DNA ligase. The ligation product was transformed into competent
E. coli DH5
, and recombinant clones were screened for
reactivity with MAb 10F3 by a colony blot assay described elsewhere
(21). The plasmid construct present in one of the MAb
10F3-reactive clones was designated pEP10F3. The correct in-frame
position and orientation of the 78-bp insert with respect to the GST
open reading frame were confirmed by nucleotide sequence analysis of
the relevant region of pEP10F3 with the vector-derived sequencing
primers 5'-CAATGTGCCTGGATGCGTTC-3' and
5'-CAGACAAGCTGTGACCGTCTCC-3'. Large quantities of this
fusion protein, designated GST-26, and of GST alone were produced and purified according to the manufacturer's directions for purification of GST fusion proteins.
Immunization protocol. Groups of five 2-month-old female BALB/c mice (Charles River Breeding Laboratories, Wilmington, Mass.) were immunized on day 1 by intraperitoneal injection with 50 µg of GST-26 suspended in 0.2 ml of Freund's complete adjuvant (Difco Laboratories) that had been diluted 1:1 in PBS. Control animals were immunized with GST only in adjuvant. These animals were given an intraperitoneal injection on day 28 with the same amount of protein in Freund's incomplete adjuvant (Difco Laboratories) that had been diluted 1:1 in PBS. Blood for serum preparation was obtained by standard methods on day 42. All procedures involving animals received approval from the Institutional Animal Care and Use Committee; all animals were housed in accordance with guidelines from the United States Department of Agriculture and the Association for Assessment and Accreditation of Laboratory Animal Care International.
Indirect antibody accessibility assay. An overnight BHI broth culture of M. catarrhalis O35E was diluted in PBS buffer containing 10% (vol/vol) fetal bovine serum and 0.025% (wt/vol) sodium azide to a density of 110 Klett units (ca. 109 CFU/ml) as measured with a Klett-Summerson colorimeter (Klett Manufacturing Co., New York, N.Y.). Identical portions (100 µl) of this suspension were added to 1 ml of MAb 10F3 or MAb 3F12 hybridoma culture supernatant or to 1 ml of the PBS buffer described above containing mouse antiserum at a dilution of 1:500. After incubation at 4°C with gentle agitation for 1 h, the bacterial cells were washed once and then resuspended in 1 ml of the buffer solution. Radioiodinated goat anti-mouse immunoglobulin was added, and the mixture was incubated for 1 h at 4°C with gentle agitation. The cells were then washed four times with 1 ml of the buffer solution, resuspended in 500 µl of triple detergent (22), and transferred to a 12-by-75-mm glass tube. The radioactivity present in each sample was determined by using a gamma radiation counter.
Bactericidal assay. Complement-sufficient normal adult human serum was prepared by standard methods. Complement inactivation was achieved by heating the serum for 30 min at 56°C. An M. catarrhalis BHI broth culture was grown to early logarithmic phase and diluted in Veronal-buffered saline containing 0.15% (wt/vol) gelatin (Sigma Chemicals Co.) to a concentration of 2.5 × 104 CFU/ml (28). Portions (100 µl) of this cell suspension were added to 100 µl of native or heat-inactivated normal human serum containing either 15 µg of purified MAb 10F3 or heat-inactivated antiserum in final dilutions of 1:20 to 1:2,000. This mixture was then incubated at 37°C. At time zero and at 60 and 120 min after the start of the assay, 10-µl aliquots were removed, suspended in 75 µl of BHI broth, and spread onto prewarmed BHI agar plates which were then incubated overnight to determine the number of CFU in each sample.
Nucleotide sequence accession numbers. The nucleotide sequences of the copB genes from M. catarrhalis O12E, TTA24, and O46E have been submitted to GenBank and assigned the accession numbers U69981, U69980, and U69982, respectively.
| |
RESULTS |
|---|
|
|
|---|
Cloning of the copB gene from M. catarrhalis TTA24. As a first step in localizing the epitope that bound MAb 10F3, the amino acid sequence of the CopB protein from an M. catarrhalis strain unreactive with this MAb (i.e., strain TTA24) was determined. A 1.3-kb PvuII-XbaI fragment from the M. catarrhalis O35E copB gene (26) was used to screen a genomic library constructed from M. catarrhalis TTA24 in the plasmid vector pBR322. Whole-cell lysates prepared from recombinant E. coli clones that hybridized this DNA probe were probed in Western blot analysis with rabbit antiserum raised against outer membrane vesicles from M. catarrhalis TTA24. One of these recombinant clones which expressed an 80-kDa protein reactive with this antiserum was shown to contain a 7.8-kb PstI DNA insert (data not shown), as was expected from previous Southern blot-based analysis of the conservation of the copB gene among M. catarrhalis strains (26). The recombinant plasmid was designated pTTA100, and a 2.6-kb HinfI fragment from this plasmid that was predicted to contain the entire copB gene was subcloned into pBluescript to obtain the recombinant plasmid pTTA150. Nucleotide sequence analysis of both strands of this 2.6-kb DNA fragment confirmed that it contained the complete copB gene from strain TTA24.
Nucleotide sequence analysis of copB genes from additional M. catarrhalis strains. To obtain information about the amino acid sequence of other CopB proteins, the copB genes from a MAb 10F3-reactive strain (O12E) and a MAb 10F3-unreactive strain (O46E) were amplified from the chromosome of each strain by PCR. The oligonucleotide primers (5'-CAAGCCTCATAATCGGAG-3') and 5'-CCTCCAGTGAAATCGAATC-3') were derived from the sequence of the copB gene of strain O35E (26) and were located just outside the open reading frame. Both strands of these two PCR products were sequenced in their entirety.
Comparison of the CopB proteins from MAb 10F3-reactive and -unreactive strains. In an attempt to localize the epitope for MAb 10F3 within the CopB protein, the deduced amino acid sequences of the CopB proteins from these four strains were compared (Fig. 1). These sequences included the leader peptide, the existence of which was confirmed previously by N-terminal amino acid sequence analysis of the mature CopB protein from M. catarrhalis O35E (26). The overall identities among these four proteins were striking, with the level of identity between the two most dissimilar proteins (i.e., those of strains O35E and O46E) being 91%. Interestingly, the reactivity of these CopB proteins with MAb 10F3 was not indicative of the degree of identity among these proteins. For example, the MAb 10F3-reactive protein from strain O35E and 98% identical to the MAb 10F3-unreactive CopB protein from strain TTA24 and only 94% identical to the MAb 10F3-reactive protein from strain O12E (Fig. 1).
|
Mapping of the MAb 10F3-reactive epitope. Oligopeptides spanning the five regions of dissimilarity between the CopB proteins of strains O35E and TTA24 were synthesized; these contained the amino acid sequences from the MAb 10F3-reactive CopB protein of strain O35E (underlined sequences in Fig. 1). These peptides were designated R1 through R5 and had amino acid sequences as follows: R1, LDIEKDKKKRTDEQLQAELDNKYAGK; R2, DANGKLVADLDRNNPTQRE; R3, NLEWTGKNLGFANE; R4, DSPSNMHVVATGANINFDK; and R5, RPGFQNQEKTD.
The abilities of these peptides to bind MAb 10F3 were investigated by means of a direct ELISA. When sodium carbonate coating buffer was used to affix the five peptides to the microtiter wells, none of them bound MAb 10F3. Variations in the pH and salt concentration of this coating buffer and variation of the coating temperature did not result in detectable binding of MAb 10F3 to any of these peptides. When 100-µl portions of MAb 10F3 hybridoma culture supernatant were preincubated with various concentrations of the five peptides and then used to probe microtiter wells coated with outer membrane vesicles of strain O35E, there was no concentration-dependent reduction of MAb 10F3-binding by any of the five peptides (data not shown). However, when glutaraldehyde was added to a final concentration of 2% to the five peptides dissolved in coating buffer, wells coated with the 26-residue peptide R1 (Fig. 2) readily bound MAb 10F3. In contrast, none of the other four peptides bound this MAb. The negative control MAb 17C7 did not bind any of these peptides (data not shown).
|
|
-helical structure, while the
binding site for MAb 10F3 is predicted to form a
-turn (Fig. 4).
|
Immunogenicity of the GST-26 fusion protein. To determine whether the peptide sequence of R1 could induce the synthesis of antibodies to CopB that would bind to the surface of M. catarrhalis, this 26-residue peptide was expressed in a fusion construct (GST-26) at the C terminus of the 26-kDa GST protein and used to immunize mice. As expected, the molecular mass of purified GST-26 was approximately 30 kDa (Fig. 5, lanes 5) and was strongly reactive with MAb 10F3 in Western blot analysis (Fig. 5A, lane 5), while GST alone was unreactive with this MAb (Fig. 5A, lane 6). GST-26 was also strongly reactive with MAb 10F3 when used as the antigen in the direct ELISA system (data not shown).
|
Binding of GST-26 antibodies to the cell surface of M. catarrhalis. The MAb 10F3-reactive epitope of CopB has been shown to be expressed on the bacterial surface (26). Because the GST-26 antiserum was shown to contain antibodies specifically binding to the CopB protein from strain O35E and also to region 1 of strain TTA24 (by ELISA with R1-TTA24 [Fig. 2]), it was of interest to determine whether antibodies derived from this antiserum would bind to the cell surface of M. catarrhalis. The use of the indirect antibody accessibility assay with whole cells of M. catarrhalis O35E, TTA24, O12E, and O46E as antigen demonstrated that, as expected, MAb 10F3 readily bound to the surface of strains O35E and O12E but not strains TTA24 and O46E (Table 2). Similarly, antibodies in the GST-26 antiserum exhibited specific binding to whole cells of strain O35E, while antibodies present in the control antiserum raised against GST did not (Table 2).
|
Bactericidal activity of MAb 10F3 and of GST-26 antiserum. MAb 10F3 was previously shown to enhance pulmonary clearance of M. catarrhalis from the lungs of mice passively immunized with this MAb (26). However, the functional basis for this MAb-accelerated elimination of bacteria from the lower respiratory tract was not determined. Therefore, the ability of MAb 10F3 to kill M. catarrhalis in the presence of human complement was evaluated by performing bactericidal assays with the MAb 10F3-reactive strains O35E and O12E and with the MAb 10F3-unreactive strains TTA24 and O46E. Similarly, the bactericidal activities of the antisera raised against GST-26 and GST (negative control) were tested, because GST-26 contained antibodies directed at the surface of strains O35E, O12E, and TTA24.
All four M. catarrhalis strains were resistant to killing by complement-sufficient normal human serum in the absence of specific antibody (Fig. 6). In the presence of normal human serum, strains O35E (Fig. 6A) and O12E (Fig. 6B) were readily killed by MAb 10F3. The MAb 10F3-unreactive strains TTA24 and O46E were not killed by MAb 10F3 (Fig. 6C and D). MAb 10F3 did not kill any of these four strains when heat-inactivated normal human serum was used in place of complement-sufficient normal human serum (Fig. 6).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
It has been documented that infections caused by M. catarrhalis induce an antibody response directed against this pathogen (6, 8, 16, 17, 19, 20, 44) and that some of these antibodies have the potential to exert biologic activity via complement-dependent killing (6) or opsonophagocytosis (16). However, with a few exceptions (20, 44), the identity of the target antigen(s) remains unclear, because in most studies, whole bacteria or crude outer membrane preparations were used as antigens to detect M. catarrhalis-directed antibodies. To date, the only M. catarrhalis outer membrane antigens that have been shown to be targets for antibodies that can exert protective effects in an animal model are the CopB and UspA proteins (7, 26, 27) while antibodies to protein CD have been reported to be bactericidal in vitro (46).
Several lines of evidence indicate that portions of the CopB protein are exposed on the surface of M. catarrhalis. These include (i) the reactivity of the CopB-specific MAb 10F3 with a surface-exposed epitope (26), (ii) the bactericidal activity of MAb 10F3 against strains that react with this MAb (Fig. 6), and (iii) the likely function of the CopB protein in a TonB-dependent physiologic process (2). In addition, FrpB, an iron-regulated outer membrane protein of Neisseria meningitidis that is 49% identical to the CopB protein of strain O35E, has also been shown to be a target for bactericidal antibody (39, 40).
Comparison of the deduced amino acid sequences of the CopB proteins from four M. catarrhalis strains revealed that reactivity with MAb 10F3 was not an indicator of similarity between CopB proteins. Furthermore, the primary amino acid sequence of this protein was very well conserved among these four strains. The level of identity among these four CopB proteins proved to be greater than 90%, a finding which is somewhat encouraging from the standpoint of vaccine development. A similar level of amino acid sequence conservation has been reported for the CD outer membrane protein of M. catarrhalis (29).
The facts that the MAb 10F3-reactive epitope was detected in the majority of M. catarrhalis strains (26) and that this epitope induced the synthesis of antibodies that were biologically active both in vivo (26) and in vitro (Fig. 6) made the determination of this epitope's location within the CopB protein an important step in the evaluation of CopB as a potential vaccine candidate. This task was facilitated considerably by the finding that the deduced amino acid sequence differences between the CopB protein of the MAb 10F3-reactive strain O35E and that of the MAb 10F3-unreactive strain TTA24 were limited to five well-defined regions (Fig. 1), one of which had to contain the MAb 10F3-reactive epitope. The analyses of the copB genes from two other M. catarrhalis strains reinforced the likelihood that one of these five regions bound MAb 10F3 and prompted the synthesis of oligopeptides that contained the corresponding amino acid sequences from the CopB protein of strain O35E.
The use of these synthetic peptides in an ELISA identified region 1 as the sequence containing the MAb 10F3-reactive epitope. Unexpectedly, binding of MAb 10F3 to peptide R1 (Fig. 2) required the presence of the cross-linking agent glutaraldehyde during the coating of the polystyrene surface of the ELISA plate with this peptide. At first, it was thought that either inherently poor binding of R1 to the microtiter well or binding of R1 to the well via the MAb 10F3-reactive residues was responsible for this finding. However, the failure of soluble R1 to bind MAb 10F3 in an inhibition assay as well as the subsequent observation that GST-26 antiserum readily bound to microtiter wells coated with R1 in the absence of glutaraldehyde invalidated these hypotheses and made conformational changes of R1 caused by glutaraldehyde a more plausible explanation. Glutaraldehyde preferentially cross-links amino groups of lysine residues such as those present in both the N- and C-terminal portions of R1 (Fig. 2). Cross-linking of these lysine residues may have led to the formation of a loop-like structure that more closely resembled the native conformation of the MAb 10F3-reactive epitope. This hypothesis is supported by the lack of binding of MAb 10F3 by peptide R1E (Fig. 2) which, as was subsequently determined, contained the binding site for MAb 10F3 but lacked the lysine-rich N-terminal portion of R1.
Differential binding of MAb 10F3 to the peptides R1A and R1B (Fig. 2) indicated that this MAb likely bound the C-terminal portion of R1 and that the asparagine (N) residue in position 21 was essential for binding. This assumption was confirmed by fine mapping of the MAb 10F3-reactive epitope by using overlapping decapeptides (Fig. 3), which demonstrated optimal binding of MAb 10F3 to a decapeptide that corresponded to residues 19 to 28 of region 1 (i.e., residues 293 to 302 of the CopB protein). This epitope comprises the C-terminal portion of a highly hydrophilic domain when analyzed by means of the hydropathy algorithm of Kyte and Doolittle (31) (Fig. 4). This finding is in keeping with the proven, bacterial cell surface-exposed location of the binding site for MAb 10F3. It is also noteworthy that the MAb 10F3-reactive epitope appears to be part of the largest variable region of the otherwise highly conserved CopB proteins studied here (Fig. 1). This finding is reminiscent of those for other well-studied bacterial outer membrane proteins, such as the MOMP P2 of nontypeable Haemophilus influenzae, for which it has been demonstrated that some surface-exposed domains exhibit strain-specific antigenicity (13, 14, 23, 47).
Characterization of the immune response directed against the GST-26 fusion protein containing the MAb 10F3 binding site revealed that, in Western blot analysis, antibodies in the GST-26 antiserum bound the CopB protein of strain O35E but not the CopB protein of the equally MAb 10F3-reactive strain O12E (Fig. 5B). This result suggested that these polyclonal antibodies did not possess the same antigenic specificity as MAb 10F3. In fact, the strong reactivity of the GST-26 antiserum with the MAb 10F3-unreactive peptides R1B and R1-TTA24 (Fig. 2) suggested that most of these polyclonal antibodies are directed against epitopes of peptide R1 other than that which binds MAb 10F3. The reduced reactivity of GST-26 antiserum with peptide R1E, which consisted of the 15 C-terminal residues of peptide R1, indicated that, not unexpectedly, some of the antibodies in the GST-26 antiserum are directed against epitopes located in the N-terminal portion of peptide R1.
Antibodies raised against GST-26 bound to the surface of whole cells of M. catarrhalis O35E, O12E, and TTA24 (Table 2) but exerted bactericidal activity against only strain O12E (Fig. 6). That these polyclonal antibodies, raised against this strain O35E-derived region 1 sequence (Fig. 2) could bind to strains O12E and TTA24 is not surprising when one considers that this same region of the CopB proteins of these other two strains was 73 to 80% identical to that of strain O35E (Fig. 2). It is also likely that these polyclonal antibodies had relatively low binding affinities which precluded their detection in Western blot analysis. However, the fact that these same surface-directed antibodies killed only strain O12E and not the homologous strain O35E or the heterologous strain TTA24 is more difficult to explain.
One possibility is the presence of an immunodominant determinant in the R1 region that induced the synthesis of blocking antibodies that bound to the R1 region of CopB of strains O35E and TTA24 but which were unreactive with the R1 region of CopB of strain O12E. Alternatively, there may have been other blocking antibodies in the mouse antiserum or in the normal human serum used as the source of complement in these experiments; these blocking antibodies could be directed against a surface determinant of strains O35E and TTA24 that was absent on strain O12E. In fact, Western blot analysis of the normal human serum used as the source of complement revealed that it contained antibodies that bound M. catarrhalis antigens (Fig. 7). The fact that antigens of strain O35E apparently bound more of these normal human serum antibodies than did strain O12E (Fig. 7) gives some credence to the possibility that blocking antibodies may be involved in the inability of the GST-26 antiserum to kill strain O35E. In this regard, noted that the existence of normal human serum antibodies reactive with one or more M. catarrhalis outer membrane proteins with apparent molecular masses of approximately 80 kDa was reported some time ago by Goldblatt and colleagues (20). Investigation of the possible involvement of blocking antibodies in this inability of the GST-26 antiserum to kill strain O35E is beyond the scope of the present study.
In summary, comparison of the deduced amino acid sequences of the CopB proteins from four strains of M. catarrhalis revealed a striking degree of identity among these macromolecules. This conservation of the primary amino acid sequence of the CopB protein among strains of this pathogen was crucial for localization of the protective epitope on the CopB protein of M. catarrhalis O35E that is recognized by the bactericidal MAb 10F3. Immunization with a fusion protein reactive with MAb 10F3 induced the synthesis of CopB-specific antibodies bactericidal for at least one MAb 10F3-reactive strain of M. catarrhalis. Further work will be necessary to determine (i) whether immunization with larger CopB peptides or with purified CopB protein can induce an immune response that is bactericidal as well as cross-reactive and (ii) whether blocking antibodies will affect the biological activity of polyclonal CopB antibodies.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by U.S. Public Health Service Grant AI-36344 and by an Advanced Technology Project award (003660-087) from the Texas Higher Education Coordinating Board to E.J.H. C.A. was supported by grants from the National Research Foundation of Switzerland and from Novartis AG, Basel, Switzerland.
We thank Steven Berk and John D. Nelson for providing the clinical isolates of M. catarrhalis used in this study.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75235-9048. Phone: (214) 648-5974. Fax: (214) 648-5905. E-mail: hansen01{at}utsw.swmed.edu.
Editor: R. E. McCallum
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Anonymous. 1989. Consensus. Pediatr. Infect. Dis. J. 8:S94-S97. |
| 1a. | Aebi, C., L. D. Cope, J. L. Latimer, S. E. Thomas, C. A. Slaughter, G. H. McCracken, and E. J. Hansen. 1996. Moraxella catarrhalis outer membrane protein CopB: identification of a peptide that contains a protective epitope, abstr. 783, p. 158. Abstracts of the 36th International Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 2. | Aebi, C., B. Stone, M. Beucher, L. D. Cope, I. Maciver, S. E. Thomas, G. H. McCracken, Jr., P. F. Sparling, and E. J. Hansen. 1996. Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin. Infect. Immun. 64:2024-2030[Abstract]. |
| 3. | Aspin, M. M., A. Hoberman, J. McCarty, S. E. McLinn, S. Aronoff, D. J. Lang, and A. Arrieta. 1995. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. J. Pediatr. 126:677-678[Medline]. |
| 4. | Bartos, L. C., and T. F. Murphy. 1988. Comparison of the outer membrane proteins of 50 strains of Branhamella catarrhalis. J. Infect. Dis. 158:761-765[Medline]. |
| 5. |
Campagnari, A. A.,
K. L. Shanks, and D. W. Dyer.
1994.
Growth of Moraxella catarrhalis with human transferrin and lactoferrin: expression of iron-repressible proteins without siderophore production.
Infect. Immun.
62:4909-4914 |
| 6. | Chapman, A. J., Jr., D. M. Musher, S. Jonsson, J. E. Clarridge, and R. J. Wallace, Jr. 1985. Development of bacterial antibody during Branhamella catarrhalis infection. J. Infect. Dis. 151:878-882[Medline]. |
| 7. | Chen, D., J. C. McMichael, K. R. van der Meid, D. Hahn, T. Mininni, J. Cowell, and J. Eldridge. 1996. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect. Immun. 64:1900-1905[Abstract]. |
| 8. | Chi, D. S., A. Verghese, C. Moore, F. Hamati, and S. L. Berk. 1990. Antibody response to P-protein in patients with Branhamella catarrhalis infections. Am. J. Med. 88(5A):25S-27S[Medline]. |
| 9. | Chou, P. Y., and G. D. Fasman. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. Adv. Enzymol. 47:45-148. |
| 10. | Davies, B. I., and F. P. V. Maesen. 1988. The epidemiology of respiratory tract pathogens in Southern Netherlands. Eur. Respir. J. 1:415-420[Abstract]. |
| 11. | Del Beccaro, M. A., P. M. Mendelman, A. F. Inglis, M. A. Richardson, N. O. Duncan, C. R. Clausen, and T. L. Stull. 1992. Bacteriology of acute otitis media: a new perspective. J. Pediatr. 120:81-84[Medline]. |
| 12. |
Doern, G. V.,
M. J. Miller, and R. E. Winn.
1981.
Branhamella (Neisseria) catarrhalis systemic disease in humans.
Arch. Intern. Med.
141:1690-1692 |
| 13. | Duim, B., L. van Alphen, P. P. Eijk, H. M. Jansen, and J. Dankert. 1994. Antigenic drift of non-encapsulated Haemophilus influenzae major outer membrane protein P2 in patients with chronic bronchitis is caused by point mutations. Mol. Microbiol. 11:1181-1189[Medline]. |
| 14. | Duim, B., L. Vogel, W. Puijk, H. M. Jansen, R. H. Meloen, J. Dankert, and L. van Alphen. 1996. Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae. Infect. Immun. 64:4673-4679[Abstract]. |
| 15. | Ey, P. I., S. J. Prowse, and C. R. Jenkin. 1978. Isolation of pure IgG1, IgG2a, and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 15:429-436[Medline]. |
| 16. | Faden, H., J. J. Hong, and N. Pahade. 1994. Immune response to Moraxella catarrhalis in children with otitis media: opsonophagocytosis with antigen-coated latex beads. Ann. Otol. Rhinol. Laryngol. 103:522-524[Medline]. |
| 17. |
Faden, H. S.,
J. J. Hong, and T. F. Murphy.
1992.
Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media.
Infect. Immun.
60:3824-3829 |
| 18. |
Gan, V. N.,
H. Kusmiesz,
S. Shelton, and J. D. Nelson.
1991.
Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.
Antimicrob. Agents Chemother.
35:967-971 |
| 19. | Goldblatt, D., N. D. Seymour, R. J. Levinsky, and M. W. Turner. 1990. An enzyme-linked immunosorbent assay for the determination of human IgG subclass antibodies directed against Branhamella catarrhalis. J. Immunol. Methods 128:219-225[Medline]. |
| 20. | Goldblatt, D., M. W. Turner, and R. J. Levinsky. 1990. Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood. J. Infect. Dis. 162:1128-1135[Medline]. |
| 21. |
Gulig, P. A.,
C. F. Frisch, and E. J. Hansen.
1983.
A set of two monoclonal antibodies specific for the cell surface-exposed 39K major outer membrane protein of Haemophilus influenzae type b defines all strains of this pathogen.
Infect. Immun.
42:516-524 |
| 22. |
Gulig, P. A.,
G. H. McCracken, Jr.,
C. F. Frisch,
K. H. Johnston, and E. J. Hansen.
1982.
Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease.
Infect. Immun.
37:82-88 |
| 23. |
Haase, E. M.,
K. Yi,
G. D. Morse, and T. F. Murphy.
1994.
Mapping of bacterial epitopes on the P2 porin protein of nontypeable Haemophilus influenzae.
Infect. Immun.
62:3712-3722 |
| 24. | Hager, H., A. Verghese, S. Alvarez, and S. L. Berk. 1987. Branhamella catarrhalis respiratory infections. Rev. Infect. Dis. 9:1140-1149[Medline]. |
| 25. | Helminen, M. E., R. Beach, I. Maciver, G. P. Jarosik, E. J. Hansen, and M. Leinonen. 1995. Human immune response against outer membrane proteins of Moraxella (Branhamella) catarrhalis determined by immunoblotting and enzyme immunoassay. Clin. Diagn. Lab. Immunol. 2:35-39[Abstract]. |
| 26. |
Helminen, M. E.,
I. Maciver,
J. L. Latimer,
L. D. Cope,
G. H. McCracken, Jr., and E. J. Hansen.
1993.
A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.
Infect. Immun.
61:2003-2010 |
| 27. | Helminen, M. E., I. Maciver, J. L. Latimer, J. Klesney-Tait, L. D. Cope, M. M. Paris, G. H. McCracken, Jr., and E. J. Hansen. 1994. A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies. J. Infect. Dis. 170:867-872[Medline]. |
| 28. | Helminen, M. E., I. Maciver, J. L. Latimer, S. R. Lumbley, L. D. Cope, G. H. McCracken, Jr., and E. J. Hansen. 1993. A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival of this organism in vivo. J. Infect. Dis. 168:1194-1201[Medline]. |
| 29. |
Hsiao, C. B.,
S. Sethi, and T. F. Murphy.
1995.
Outer membrane protein CD of Branhamella catarrhalis sequence conservation in stains recovered from the human respiratory tract.
Microb. Pathog.
19:215-225[Medline].
|
| 30. | Kabat, E. A. 1970. Heterogeneity and structure of antibody-combining sites. Ann. N. Y. Acad. Sci. 169:43-54[Medline]. |
| 31. | Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132[Medline]. |
| 32. | Maciver, I., M. Unhanand, G. H. McCracken, Jr., and E. J. Hansen. 1993. Effect of immunization on pulmonary clearance of Moraxella catarrhalis in an animal model. J. Infect. Dis. 168:469-472[Medline]. |
| 33. | Malkamaki, M., E. Honkanen, M. Leinonen, and P. H. Makela. 1983. Branhamella catarrhalis as a cause of bacteremic pneumonia. Scand. J. Infect. Dis. 15:125-126[Medline]. |
| 34. | McLeod, D. T., F. Ahmad, S. Capewell, M. J. Croughan, M. A. Calder, and A. Seaton. 1986. Increase in bronchopulmonary infection due to Branhamella catarrhalis. Br. Med. J. Clin. Res. 292:1103-1105. |
| 35. |
Murphy, T. F., and L. C. Bartos.
1989.
Surface exposed and antigenically conserved determinants of outer membrane proteins of Branhamella catarrhalis.
Infect. Immun.
57:2938-2941 |
| 36. | Murphy, T. F., C. Kirkham, and A. J. Lesse. 1993. The major heat-modifiable outer membrane protein CD is highly conserved among strains of Branhamella catarrhalis. Mol. Microbiol. 10:87-97[Medline]. |
| 37. | Murphy, T. F., and M. R. Loeb. 1989. Isolation of the outer membrane of Branhamella catarrhalis. Microb. Pathog. 6:159-174[Medline]. |
| 38. |
Nicotra, B.,
M. Rivera,
J. I. Liman, and R. J. Wallace.
1986.
Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease.
Arch. Intern. Med.
146:890-893 |
| 39. |
Pettersson, A.,
B. Kuipers,
M. Pelzer,
E. Verhagen,
R. H. Tiesjema,
J. Tommassen, and J. T. Poolman.
1990.
Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.
Infect. Immun.
58:3036-3041 |
| 40. | Pettersson, A., A. Maas, D. van Wassenaar, P. van der Ley, and J. Tommassen. 1995. Molecular cloning of FrpB, the 70-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis. Infect. Immun. 63:4181-4184[Abstract]. |
| 41. |
Post, J. C.,
R. A. Preston,
J. J. Aul,
M. Larkins-Pettigrew,
J. Rydquist-White,
K. W. Anderson,
R. M. Wadowsky,
D. R. Reagan,
E. S. Walker,
L. A. Kingsley,
A. E. Magit, and G. D. Ehrlich.
1995.
Molecular analysis of bacterial pathogens in otitis media with effusion.
JAMA
273:1598-1604 |
| 42. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. . Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 43. | Schechter, I. 1971. Mapping of the combined sites of antibodies specific to polyalanine chains. Ann. N. Y. Acad. Sci. 190:394-419[Medline]. |
| 44. | Sethi, S., S. L. Hill, and T. F. Murphy. 1995. Serum antibodies to outer membrane proteins (OMPs) of Moraxella (Branhamella) catarrhalis in patients with bronchiectasis: identification of OMP B1 as an important antigen. Infect. Immun. 63:1516-1520[Abstract]. |
| 45. |
Vaneechoutte, M.,
G. Verschraegen,
G. Claeys, and A. M. van den Abeele.
1990.
Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum.
J. Clin. Microbiol.
28:2674-2680 |
| 46. | Yang, Y.-P., L. E. Myers, U. Mcguinness, P. Chong, Y. Kwok, M. H. Klein, and R. E. Harkness. 1997. The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol. Med. Microbiol. 17:187-199[Medline]. |
| 47. | Yi, K., and T. F. Murphy. 1994. Mapping of a strain-specific bacterial epitope to the surface-exposed loop 5 on the P2 porin protein of non-typeable Haemophilus influenzae. Microb. Pathog. 17:277-282[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»